CLNN
Clene Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.10
+8.75%Nov 4, 2026, 16:06 UTC
Clene Inc. reported quarterly earnings of $0.05 per share, compared with a loss of $0.85 per share a year earlier.
Source:Nov 4, 2026, 13:30 UTC
Clene Inc. announced its third-quarter 2026 financial results and operating highlights.
Source:Oct 19, 2026, 12:00 UTC
Clene Inc. submitted a New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis.
Source:Sep 21, 2026, 12:31 UTC
Clene completed a $4 million registered direct offering, extending its cash runway beyond the FDA's decision on the CNM-Au8 new drug application.
Sep 15, 2026, 13:00 UTC
Clene Inc. priced a $4 million registered direct offering of 1,219,513 shares at $3.28 per share to existing shareholders, including insiders.
Source:Aug 14, 2026, 14:22 UTC
Clene Inc. reported a quarterly loss of $0.6 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.37, but beating revenue estimates.
Source:Aug 12, 2026, 10:02 UTC
Clene announced it will submit a new drug application (NDA) for CNM-Au8 as an ALS treatment in early Q4 2026, following FDA meetings.
Source: